In a report issued on July 14, Do Kim from BMO Capital maintained a Buy rating on Ionis Pharmaceuticals (IONS – Research Report), with a price target of $86.00. The company’s shares closed last Thursday at $59.70.
According to TipRanks.com, Kim is a 5-star analyst with an average return of 29.2% and a 60.4% success rate. Kim covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals, Vertex Pharmaceuticals, and Bioxcel Therapeutics.
Ionis Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $76.40, implying a 25.7% upside from current levels. In a report issued on July 15, Needham also assigned a Buy rating to the stock with a $89.00 price target.
Ionis Pharmaceuticals’ market cap is currently $8.32B and has a P/E ratio of 54.70. The company has a Price to Book ratio of 6.34.
Based on the recent corporate insider activity of 51 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of IONS in relation to earlier this year. Earlier this month, Frederick Muto, a Director at IONS bought 15,000 shares for a total of $138,300.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics segments. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The Akcea Therapeutics segment develops and commercializes drugs for cardiometabolic diseases. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli and Brett P. Monia in 1989 and is headquartered in Carlsbad, CA.